ECOR - רווח נקי למניה (EPS TTM) electroCore Medical

Unique patents provide electroCore, Inc. (ECOR) with pricing power, although insurance bureaucracy is constraining revenue. Experienced management is focusing on clinical evidence and expanding insurance coverage. The current trailing twelve-month net income per share clearly demonstrates fundamental earnings, where -1.44 forms the current metric value. This chart confirms that the patent-protected niche of non-invasive vagus nerve stimulation precludes direct technology replication.

For electroCore, Inc. (ECOR), which developed a non-drug migraine treatment via nerve stimulation, the fundamental EPS TTM metric reflects the monetization efficiency of this innovation. This metric measures the trailing twelve-month net income allocated per share. The value is derived by dividing the total income over the last 12 months by the total number of shares outstanding. The trend of the curve allows for an assessment of the actual return on capital, while the indicator's growth confirms the sustainability of the business model.